Paige.AI

Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.

Applications by this vendor

Paige Prostate Perinueral Invasion

CE | H&E

Paige Prostate Perineural Invasion (PNI) aids pathologists in identifying the presence of suspicious foci around nerve fibers within the prostate for detection of PNI in core needle biopsies.

Paige Prostate Grade and Quantify

CE | H&E

Paige Prostate Grade & Quantify uses a proprietary tissue map to categorize areas suspicious for cancer by Gleason pattern to assist pathologists in evaluating values for overall tumor percentage and tumor length.

Paige Prostate Biomarker Panel

CE | H&E

Paige Prostate Biomarker Panel is comprised of four AI models used to identify biomarkers including Androgen Receptor (AR) amplification, TP53, RB1 and PTEN mutations, based on the assessment of H&E-stained primary and metastatic prostate samples.

Paige Breast

CE | H&E

Paige Breast is a digital diagnostic aid for assisting pathologists with detecting and classifying carcinoma and atypical lesions on H&E stained WSIs of breast tissue.

Paige Breast Lymph Node

CE | H&E

Paige Breast Lymph Node is designed to aid pathologists in the detection of metastases in breast lymph node, guiding pathologists to areas suspicious for metastases including ITCs and small challenging micromets to improve diagnostic confidence.

Paige Prostate Detect

CE & FDA | H&E

Paige Prostate Detect assists pathologists in the detection of suspicious foci, highlighting the region of interest with the highest likelihood of harboring cancer to help improve diagnostic sensitivity.